Molecular Tumor Board: Series 10 || Interesting Cases || Don't Miss || Every Month 2nd&4th Saturday
Автор: MedEdge Series
Загружено: 2025-11-09
Просмотров: 78
▶️Watch Now 📌Subscribe Now
🧬 ALK fusion + TP53 loss — Oncogenic driver active, tumor suppressor silenced.
🧬 KRAS + APC + TP53 — Colorectal mutational signature in pancreatic tissue.
🩸 HER2 3+ / ER+ / PIK3CA mut — Dual pathway activation; trastuzumab resistance likely via PI3K escape.
💠 ERBB2 Y310C (VAF 1.8%) — Subclonal variant; not founding clone, low therapeutic priority.
🔬 BARD1 VUS — HR pathway gene alteration; functional impact undetermined, germline correlation pending.
💊 KRAS G12A — Prevalent allele, limited targeted options (sotorasib/adagrasib G12C-specific).
🧬 PIK3CA missense — PI3K/AKT axis dysregulated; endocrine therapy resistance mechanism in HR+ disease
Case 1 – 00:25
Case 2 – 41:03
Case 3 – 50:47
Case 4 – 1:40:29
Case 5 – 1:00:56
Case 6 – 1:16:15
Case 7 – 1:27:01
Case 8 – 34:58
📲 Join WhatsApp Group
https://chat.whatsapp.com/Cb3lAc6VrZD...
▶️Presented & Edited By
Prof. Arun Seshachalam
Medical Oncologist
▶️More Information
📩Email: [email protected]
📞Contact: 88258 05263
🌐Website: https://www.realworldevidence.in/
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
